Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III open-label extension study of PRM-151 in idiopathic pulmonary fibrosis
2020-001429-30Phase 3Completed
- Sponsor
- Roche
- Start
- Nov 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of zinpentraxin alfa in idiopathic pulmonary fibrosis (IPF), sponsored by Roche. Primary endpoint: Incidence and severity of adverse events. Started Nov 2020; status: completed.
02
Drugs
zinpentraxin alfa
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on 2020-001429-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001429-30.